126 related articles for article (PubMed ID: 7486953)
1. Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine.
Kodama E; Mori S; Shigeta S
Antiviral Res; 1995 May; 27(1-2):165-70. PubMed ID: 7486953
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.
Yokota T; Konno K; Shigeta S; Verbruggen A; De Clercq E
Mol Pharmacol; 1987 May; 31(5):493-9. PubMed ID: 3033468
[TBL] [Abstract][Full Text] [Related]
3. Random mutagenesis of the thymidine kinase gene of varicella-zoster virus.
Suzutani T; Lacey SF; Powell KL; Purifoy DJ; Honess RW
J Virol; 1992 Apr; 66(4):2118-24. PubMed ID: 1312622
[TBL] [Abstract][Full Text] [Related]
4. Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction.
Lacey SF; Suzutani T; Powell KL; Purifoy DJ; Honess RW
J Gen Virol; 1991 Mar; 72 ( Pt 3)():623-30. PubMed ID: 1848597
[TBL] [Abstract][Full Text] [Related]
5. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.
Andrei G; Topalis D; Fiten P; McGuigan C; Balzarini J; Opdenakker G; Snoeck R
J Virol; 2012 Mar; 86(5):2641-52. PubMed ID: 22190713
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir.
Morfin F; Thouvenot D; De Turenne-Tessier M; Lina B; Aymard M; Ooka T
Antimicrob Agents Chemother; 1999 Oct; 43(10):2412-6. PubMed ID: 10508017
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades.
Hoffmann A; Döring K; Seeger NT; Bühler M; Schacke M; Krumbholz A; Sauerbrei A
J Clin Virol; 2017 Oct; 95():61-65. PubMed ID: 28886462
[TBL] [Abstract][Full Text] [Related]
8. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a varicella-zoster virus variant with altered thymidine kinase activity.
Shigeta S; Mori S; Yokota T; Konno K; De Clercq E
Antimicrob Agents Chemother; 1986 Jun; 29(6):1053-8. PubMed ID: 3015014
[TBL] [Abstract][Full Text] [Related]
10. Kinetic studies of the predicted substrate-binding site of varicella-zoster virus thymidine kinase.
Suzutani T; Davies LC; Honess RW
J Gen Virol; 1993 Jun; 74 ( Pt 6)():1011-6. PubMed ID: 8389797
[TBL] [Abstract][Full Text] [Related]
11. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
Biken J; 1983 Mar; 26(1):17-23. PubMed ID: 6312958
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate.
Brunnemann AK; Bohn-Wippert K; Zell R; Henke A; Walther M; Braum O; Maschkowitz G; Fickenscher H; Sauerbrei A; Krumbholz A
Antimicrob Agents Chemother; 2015 May; 59(5):2726-34. PubMed ID: 25712361
[TBL] [Abstract][Full Text] [Related]
13. Homology modelling and docking studies on Varicella Zoster Virus Thymidine kinase.
Spadola L; Novellino E; Folkers G; Scapozza L
Eur J Med Chem; 2003 Apr; 38(4):413-9. PubMed ID: 12750029
[TBL] [Abstract][Full Text] [Related]
14. Therapy of varicella-zoster virus infection--mechanism of action of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Shigeta S; Yokota T; De Clercq E
Antiviral Res; 1985; Suppl 1():35-44. PubMed ID: 3002264
[No Abstract] [Full Text] [Related]
15. Molecular analysis of the thymidine kinase gene of thymidine kinase-deficient mutants of varicella-zoster virus.
Mori H; Shiraki K; Kato T; Hayakawa Y; Yamanishi K; Takahashi M
Intervirology; 1988; 29(6):301-10. PubMed ID: 2852653
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Wilber BA; Docherty JJ
J Gen Virol; 1994 Jul; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of varicella zoster virus thymidine kinase.
Bird LE; Ren J; Wright A; Leslie KD; Degrève B; Balzarini J; Stammers DK
J Biol Chem; 2003 Jul; 278(27):24680-7. PubMed ID: 12686543
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activities and phosphorylation of 5-halo-2'-deoxyuridines and N-methanocarbathymidine in cells infected with vaccinia virus.
Smee DF; Humphreys DE; Hurst BL; Barnard DL
Antivir Chem Chemother; 2008; 19(1):15-24. PubMed ID: 18610554
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS.
Boivin G; Edelman CK; Pedneault L; Talarico CL; Biron KK; Balfour HH
J Infect Dis; 1994 Jul; 170(1):68-75. PubMed ID: 8014522
[TBL] [Abstract][Full Text] [Related]
20. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
Yokota T; Konno K; Shigeta S; De Clercq E
Mol Pharmacol; 1984 Sep; 26(2):376-80. PubMed ID: 6090888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
